Krystal Biotech Total Current Liabilities

Krystal Biotech (KRYS) currently reports a total current liabilities of $130M as of June 2026. That compares with $87M in the prior-year period — up 46.6% year over year. Use the charts on this page to explore Krystal Biotech's total current liabilities history and peer comparisons.

Krystal Biotech's total current liabilities increased from $87M to $130M — a 46.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Krystal Biotech reported $130M in total current liabilities as of June 2026. That compares with $87M in the prior-year period — up 46.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Krystal Biotech, and consider following KRYS for alerts when major investors trade the stock.

Krystal Biotech is classified in the Healthcare sector. On total current liabilities, it currently shows $130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRYS with unrelated industries.